64095-60-9

Basic information

• Product Name: LONGISTYLINE A
• Synonyms: 3-Methoxy-2-(3-methyl-2-buten-1-yl)-5-[(1E)-2-phenylethenyl]phenol;Longistylin A
• CAS NO: 64095-60-9
• Molecular Formula: C₂₀H₂₂O₂
• Molecular Weight: 294.39
• Product Categories: Miscellaneous Natural Products
• Mol File: 64095-60-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 452.1±24.0 °C(Predicted)
• Appearance: /
• Density: 1.087±0.06 g/cm3(Predicted)
• PKA: 10.02±0.15(Predicted)
• CAS DataBase Reference: LONGISTYLINE A(CAS DataBase Reference)
• NIST Chemistry Reference: LONGISTYLINE A(64095-60-9)
• EPA Substance Registry System: LONGISTYLINE A(64095-60-9)

Safety Data

• Hazardous Substances Data: 64095-60-9(Hazardous Substances Data)

Usage

General Description

LONGISTYLINE A is a chemical compound isolated from the roots of the Longistylus salicifolius plant, and it belongs to the class of alkaloids. It exhibits potent anti-inflammatory and antinociceptive properties, making it a potential candidate for the treatment of pain and inflammation-related disorders. LONGISTYLINE A has also shown to possess significant inhibitory effects on the production of nitric oxide and prostaglandin E2, which are important mediators of inflammation. Additionally, it has demonstrated antioxidant activity, indicating its potential use in combating oxidative stress-related conditions. Overall, LONGISTYLINE A has shown promising pharmacological properties, making it an interesting compound for further research and potential therapeutic development.

Upstream product

• 115-18-4 2-methyl-3-buten-2-ol 
• 35302-70-6 3-methoxy-5-[(E)-2-phenylvinyl]phenol 
• 100-52-7 benzaldehyde 
• 870-63-3 prenyl bromide 
• 1363155-62-7 (E)-methyl 2-hydroxy-4-methoxy-3-(3-methylbut-2-en-1-yl)-6-styrylbenzoate 
• 1258410-99-9 (E)-2,4-dimethoxy-6-styrylbenzoic acid methyl ester 
• 70719-50-5 2-bromomethyl-4,6-dimethoxy-benzoic acid methyl ester 
• 6110-37-8 methyl 2,4-dimethoxy-6-methylbenzoate 

Relevant articles and documents

Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1

There still remains a need to develop new anti-HCV agents with distinct mechanism of action (MOA) due to the occurrence of resistance to direct-acting antiviral agents (DAAs). Cajanine, a stilbenic component isolated from Cajanus cajan L., was identified as a potent HCV inhibitor by phenotypic screening in this work (EC50 = 3.17 ± 0.75 μM). The intensive structure optimization provided significant insights into the structure-activity relationships. Furthermore, the MOA study revealed that cajanine inhibited HCV replications via down-regulating a cellular protein chondroitin sulfate N-acetylgalactosaminyltransferase 1. In consistency with this host-targeting mechanism, cajanine showed the similar magnitude of inhibitory activity against both drug-resistant and wild-type HCV and synergistically inhibited HCV replication with approved DAAs. Taken together, our study not only presented cajanine derivatives as a novel class of anti-HCV agents but also discovered a promising anti-HCV target to combat drug resistance.

CAJANINE STRUCTURE ANALOGOUS COMPOUND, PREPARATION METHOD AND USE

Provided are cajanine structure analogous compounds, synthesis method and pharmacological effects thereof, the compounds of the present invention having the structure as represented by general formulas I, II, III, IV and V. Also provided are pharmaceutical compositions containing the compounds as active ingredient, and uses thereof; the compounds of the present invention having the pharmacological activities such as anti-virus, anti-virus-infection, nerve protection, anti-metabolic-diseases and the like. Also provided is a chemical total synthesis preparation method of the natural products cajanine, cajanine A and cajanine C. The present invention lays a foundation for the in-depth study and development of the compounds as clinical drugs in the future.